XVIVO Group

October 22, 2026

XVIVO reports 34 percent sales growth in Q3 2026 and CE marking for heart technology

XVIVO's net sales rose 34 percent to SEK 252.6 million in the third quarter of 2026, with organic growth of 32 percent driven by a 51 percent increase in thoracic sales. EBITDA increased to SEK 52.0 million, giving a margin of 21 percent, while gross margin fell to 70 percent from 75 percent. During the quarter the company received CE certificates for XVIVO Heart Assist Transport, enabling commercial availability across Europe, and the FDA received its PMA application for the system. This summary was AI-generated.

Source: 

XVIVO Group

Read the original news article here